[1]武 坤a,马晓波a,杨金荣b,等.成人噬血细胞综合征患者血浆IL-6，IL-8 和IL-10 水平分析及其与预后的相关性研究[J].现代检验医学杂志,2023,38(06):19-22+124.[doi:10.3969/j.issn.1671-7414.2023.06.004]
　WU Kuna,MA Xiaoboa,YANG Jinrongb,et al.Analysis of IL-6, IL-8 and IL-10 Levels in Adult Patients with Hemophagocytic Syndrome and Their Correlation with Prognosis[J].Journal of Modern Laboratory Medicine,2023,38(06):19-22+124.[doi:10.3969/j.issn.1671-7414.2023.06.004]
点击复制

成人噬血细胞综合征患者血浆IL-6，IL-8 和IL-10 水平分析及其与预后的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年06期
页码:
19-22+124
栏目:
论著
出版日期:
2023-11-15

文章信息/Info

Title:
Analysis of IL-6, IL-8 and IL-10 Levels in Adult Patients with Hemophagocytic Syndrome and Their Correlation with Prognosis
文章编号:
1671-7414（2023）06-019-05
作者:
武 坤1; 2; 3a; 马晓波1; 2; 3a; 杨金荣3b; 4; 聂 波3b; 4; 周 强3b; 4; 程沈菊1; 2; 3a; 罗 珊1; 2; 3a; 曾 云3b; 4
（1. 云南省检验医学重点实验室，昆明 650032；2. 云南省医学检验临床医学研究中心，昆明 650032；3. 昆明医科大学第一附属医院 a. 医学检验科；b. 血液科，昆明 650032; 4. 云南省血液病研究中心，昆明 650032）
Author(s):
WU Kun1; 2; 3a;  MA Xiaobo1; 2; 3a;  YANG Jinrong3b; 4;  NIE Bo3b; 4;  ZHOU Qiang3b; 4;  CHENG Shenju1; 2; 3a;  LUO Shan1; 2; 3a;  ZENG Yun 3b; 4
（1. Yunnan Key Laboratory of Laboratory Medicine, Kunming 650032, China; 2. Yunnan Institute of Laboratory and Clinical Medicine，Kunming 650032, China; 3a.Department of Clinical Laboratory; 3b. Department of Hematology, the First Affiliated Hospital of Kunming Medical University, Kunming 650032, China; 4. Yunnan Institute of Hematology, Kunming 650032, China）
关键词:
噬血细胞综合征; 白细胞介素-6; 白细胞介素-8; 白细胞介素-10
分类号:
R593.3；R392.11
DOI:
10.3969/j.issn.1671-7414.2023.06.004
文献标志码:
A
摘要:
目的 检测成人噬血细胞综合征（hemophagocytic syndrome，HPS）患者血浆IL-6，IL-8 和IL-10 水平，并分析其与预后相关性。方法 选取2018 年1 月～ 2021 年1 月昆明医科大学第一附属医院收治的成人噬血细胞综合征患者60例为研究对象（HPS 组），根据患者处于急性期或缓解期分为急性期组（n=32）和缓解期组（n=28），根据患者结局分为存活组（n=51）和死亡组（n=9）。选择同期60 例健康体检人群作为对照组。采用流式细胞术分析血液中免疫活性细胞含量、血浆IL-8，IL-10 和IL-6 水平。对患者进行随访，采用Kaplan-Meier 法分析细胞因子IL-8，IL-10，IL-6 表达水平与患者生存时间的关系。结果 HPS 组NK 细胞检出率（15.59%±2.81%）显著低于对照组（23.92%±3.92%），CTL 细胞（31.07%±3.29%）、单核细胞（7.59%±1.84%）检出率显著高于对照组（22.53%±5.41%，5.16%±1.72%），差异均有统计学意义（t=12.969，11.224，8.728，均P ＜ 0.05）。HPS 组血浆IL-6（83.2±9.8pg/ml），IL-8（104.8±14.3pg/ml）和IL-10（211.2±17.3pg/ml）水平显著高于对照组（31.1±7.4pg/ml，16.5±4.3pg/ml，26.9±1.9pg/ml），差异有统计学意义（t=39.824，62.382，115.630，均P＜0.05）。急性期患者IL-6（99.8±7.5pg/ml），IL-8（127.6±12.9pg/ml）和IL-10（294.9±24.1pg/ml）水平显著高于缓解期（69.1±4.1pg/ml，84.8±6.6pg/ml，137.9±7.7pg/ml），差异有统计学意义（t=20.004，16.477，34.908，均P ＜ 0.05）。死亡组患者IL-6（125.1±16.7pg/ml），IL-8（193.9±25.8pg/ml） 和IL-10（474.7±65.3pg/ml）水平显著高于存活组（75.8±6.3pg/ml，89.2±9.0pg/ml，164.7±18.7pg/ml），差异具有统计学意义（t=15.994，22.777，28.747，均P ＜ 0.05）。IL-6，IL-8，IL-10 高水平患者中位生存时间（16.4±2.8 月，14.7±3.8 月，30.5±5.1 月）明显低于低水平患者（24.7±5.3 月，24.0±1.7 月，55.3±4.7 月），差异具有统计学意义（t=7.229，23.608，35.411，均P ＜ 0.05）。随着治疗的进行，HPS 患者血浆IL-6，IL-8，IL-10 水平呈下降趋势（t=5.025，17.395，8.337，均P ＜ 0.05）。结论 细胞因子IL-6，IL-8 和IL-10 在HBS 患者血浆中水平升高，高水平血浆IL-6，IL-8，IL-10 与HBS 患者预后不佳。
Abstract:
Objective To detect IL-6, IL-8, and IL-10 levels in adult patients with hemophagocytic syndrome (HPS) and analysis of their correlation with prognosis. Methods Sixty patients with hemophagocytic syndrome admitted to the First Affiliated Hospital of Kunming Medical University from January 2018 to January 2021 were selected as the research subjects (HPS group). They were divided into acute phase group（n=32）and remission phase group（n=28） based on their acute or remission phase, survival group（n=51） and death group（n=9） based on their outcomes, and 60 healthy individuals in the same period were selected as the control group. Flow cytometry was used to analyze the content of immune active cells in the blood and plasma levels of IL-8, IL-10, and IL-6. Follow up patients and analyze the relationship between the expression levels of cytokines IL-8, IL-10 and IL-6, and patient survival time using Kaplan Meier method. Results The detection rate of NK cells（15.59%±2.81%） in the HPS group was significantly lower than that in the control group（23.92%±3.92%）, while the detection rates of CTL cells（31.07%±3.29%）and monocytes（7.59%±1.84%）were significantly higher than those in the control group （22.53%±5.41%，5.16%±1.72%） with statistically significant differences (t=12.969, 11.224, 8.728, all P<0.05). The levels of IL-6 (83.2±9.8pg/ml), IL-8 (104.8±14.3pg/ml) and IL-10 (211.2±17.3pg/ml) in HPS group were significantly higher than those in control group (31.1±7.4pg/ml, 16.5±4.3pg/ml， 26.9±1.9pg/ml), the differences were statistically significant (t=39.824，62.382，115.630, all P<0.05) . The levels of IL-6 (99.8±9.8pg/ml)，IL-8 （127.6±12.9pg/ ml） and IL-10 （294.9±24.1pg/ml） in acute phase patients were significantly higher than those in remission phase patients (69.1±4.1pg/ml, 84.8 ± 6.6pg/ml, 137.9±7.7pg/ml), with statistically significant differences(t=20.004, 16.477, 34.908, all P<0.05). . The levels of plasma IL-6 (125.1±16.7pg/ml), IL-8 (193.9± 25.8pg/ml) and IL-10 (474.7±65.3pg/ml) in the death group were significantly higher than those in the survival group (75.8±6.3pg/ml, 89.2±9.0pg/ml, 164.7±18.7pg/ml), with statistically significant differences (t=15.994, 22.777, 28.747, all P<0.05). The median survival time of patients with high levels of plasma IL-6, IL-8 and IL-10 (16.4±2.8 months, 14.7±3.8 months, 30.5±5.1 months) was significantly lower than that of patients with low levels (24.7±5.3 months, 24.0±1.7 months, 55.3±4.7 months), and the differences were statistically significant (t=7.229, 23.608, 35.411, all P<0.05). As treatment progressed, the levels of plasma IL-6, IL-8 and IL-10 in HPS patients showed a decreasing trend (t=5.025, 17.395, 8.337, all P<0.05). Conclusion The levels of cytokines plasma IL-6， IL-8 and IL-10 were elevated in HBS patients, while high levels of IL-6, IL-8 and IL-10 have poor prognosis in HBS patients.

参考文献/References:

[1] VALADE S, MARIOTTE E, AZOULAY E. Coagulation disorders in hemophagocytic lymphohistiocytosis/macrophage activation syndrome[J]. Critical Care Clinics, 2020, 36(2): 415-426.
[2] 王玲, 尹春燕, 肖延风, 等．噬血细胞综合征(HPS)的早期鉴别诊断和实验室结果分析[J]. 现代检验医学杂志, 2016, 31 (4): 107-109. WANG Ling, YIN Chunyan, XIAO Yanfeng, et al. Analysis of the etiology and clinical features of bone marrow in children with hemophagocytic phenomenon[J]. Journal of Modern Laboratory Medicine, 2016, 31(4): 107-109.
[3] HENDERSON L A, CRON R Q. Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management[J]. Pediatric Drugs, 2020, 22(1): 29-44.
[4] SOY M, ATAG?ND?Z P, ATAG?ND?Z I, et al. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic[J]. Rheumatology International, 2021, 41(1): 7-18.
[5] 张景荣, 梁筱灵, 靳蓉, 等. HLH-2004 方案诊治儿童噬血细胞综合征临床分析[J]. 中国当代儿科杂志,2013,15(8):686-688. ZHANG Jingrong, LIANG Xiaoling, JIN Rong, et al. HLH-2004 protocol:diagnostic and therapeutic guidelines for childhood hemophagocytic lymphohistiocytosis[J]. Chinese Journal of Contemporary Pediatrics,2013, 15(8): 686-688.
[6] GRIFFIN G, SHENOI S, HUGHES G C. Hemophagocytic lymphohistiocytosis: An update on pathogenesis,diagnosis, and therapy[J]. Best Practice & Research. Clinical Rheumatology, 2020, 34(4): 101515.
[7] YAO Shuyan, WANG Yini, SUN Yuan, et al. Epidemiological investigation of hemophagocytic lymphohistiocytosis in China[J]. Orphanet Journal of Rare Diseases, 2021, 16(1): 342.
[8] 黄文锋, 孔繁聪, 李菲．白细胞介素-6 阻滞治疗在噬血细胞性淋巴组织细胞增生症中的研究新进展[J]. 国际输血及血液学杂志, 2022, 45(2): 106-112. HUANG Wenfeng, KONG Fancong, LI Fei. Research advances on interleukin-6 blocking therapy in treatment of hemophagocytic lymphohistiocytic hyperplasia[J].International Journal of Blood Transfusion and Hematology,2022, 45(2): 106-112.
[9] NAKASHIMA Y, KOGA H. Using a minimal parameter set for early diagnosis of hemophagocytic lymphohistiocytosis in non-european children[J]. Am J Case Rep, 2022, 23:e934037.
[10] CHIN M, MUGISHIMA H, TAKAMURA M, et al. Hemophagocytic syndrome and hepatosplenic gammadelta T-cell lymphoma with isochromosome 7q and 8 trisomy[J]. Journal of Pediatric Hematology Oncology, 2004, 26(6): 375-378.
[11] WANG Siwen, YANG Lichuan, ZHOU Jiaojiao, et al. A prediction model for acute kidney injury in adult patients with hemophagocytic lymphohistiocytosis [J].Front Immunol, 2022, 13: 987916.
[12] B?BOL-POKORA K, WO?OWIEC M, POPKO K, et al. Molecular genetics diversity of primary hemophagocytic lymphohistiocytosis among Polish pediatric patients[J]. Archivum Immunologiae et Therapiae Experimentalis, 2021, 69(1): 31.
[13] LEE D E, MARTINEZ-ESCALA M E, SERRANO L M, et al. Hemophagocytic lymphohistiocytosis in cutaneous T-Cell lymphoma[J]. JAMA Dermatology (Chicago, Ill.), 2018, 154(7): 828-831.
[14] WAKIGUCHI H, HASEGAWA S, HIRANO R, et al. Successful control of juvenile dermatomyositisassociated macrophage activation syndrome and interstitial pneumonia: distinct kinetics of interleukin-6 and -18 levels [J]. Pediatr Rheumatol Online J, 2015,13:49.
[15] NANNO S, KOH H, NAKASHIMA Y, et al. Diagnostic value of serum ferritin and the risk factors and cytokine profiles of hemophagocytic syndrome following allogeneic hematopoietic cell transplantation[J].Leukemia & Lymphoma, 2017, 58(7): 1664-1672.
[16] KARPENKO M N, VASILISHINA A A, GROMOVA E A, et al. Interleukin-1β, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-α levels in CSF and serum in relation to the clinical diversity of Parkinson's disease [J]. Cell Immunol, 2018, 327:77-82.

相似文献/References:

[1]张　劲,明　媚.增生性糖尿病视网膜病变患者玻璃体、房水和血浆中VEGF表达与IL-6，IL-8和TNF-α水平的相关性研究[J].现代检验医学杂志,2021,36(04):55.[doi:10.3969/j.issn.1671-7414.2021.04.012]
　ZHANG Jin,MING Mei.Correlation of VEGF Expression with IL-6, IL-8 and TNF-α Levels inVitreous Body, Aqueous Humor and Plasma of Patients with ProliferativeDiabetic Retinopathy[J].Journal of Modern Laboratory Medicine,2021,36(06):55.[doi:10.3969/j.issn.1671-7414.2021.04.012]
[2]王　海,肖　华,陈兴壮.血浆miR-223-3p，PCT，IL-6和CRP水平联合检测对脓毒症实验诊断及预后的价值研究[J].现代检验医学杂志,2021,36(05):51.[doi:10.3969/j.issn.1671-7414.2021.05.011]
　WANG Hai,XIAO Hua,CHEN Xing-zhuang.Value of Combined Detection of Plasma miR-223-3p, PCT, IL-6 and CRPLevels in Experimental Diagnosis and Prognosis of Sepsis[J].Journal of Modern Laboratory Medicine,2021,36(06):51.[doi:10.3969/j.issn.1671-7414.2021.05.011]
[3]宋婷阁,张鹏举,耿　彪,等.新生儿急性呼吸窘迫综合征患者血清miR-183-5p的表达及与IL-1β，IL-6和TNF-α水平的相关性[J].现代检验医学杂志,2021,36(05):55.[doi:10.3969/j.issn.1671-7414.2021.05.012]
　SONG Ting-ge,ZHANG Peng-ju,GENG Biao,et al.Expression of Serum miR-183-5p in Patients with Neonatal Acute RespiratoryDistress Syndrome and Its Correlation with IL-1 β, IL-6 and TNF-α[J].Journal of Modern Laboratory Medicine,2021,36(06):55.[doi:10.3969/j.issn.1671-7414.2021.05.012]
[4]梁　津,刘轾彬,梁成员,等.初诊活动性肺结核患者血浆IL-6，IL-17，IL-37及TIM-3水平表达及其临床意义[J].现代检验医学杂志,2021,36(06):179.[doi:10.3969/j.issn.1671-7414.2021.06.039]
　LIANG Jin,LIU Zhi-bin,LIANG Cheng-yuan,et al.Expression and Clinical Significance of Plasma IL-6, IL-17, IL-37 and TIM-3 in Patients with Newly Diagnosed Active Pulmonary Tuberculosis[J].Journal of Modern Laboratory Medicine,2021,36(06):179.[doi:10.3969/j.issn.1671-7414.2021.06.039]
[5]那将超,狄长安.甲状腺乳头状癌患者术后血清MMIF 和IL-6 表达水平与甲状旁腺功能减退持续时间的相关性研究[J].现代检验医学杂志,2023,38(01):191.[doi:10.3969/j.issn.1671-7414.2023.01.036]
　NA Jiang-chao,DI Chang-an.Correlation between Postoperative Serum MMIF and IL-6 Expression Levels and Duration of Hypoparathyroidism in Patients with Papillary Thyroid Cancer[J].Journal of Modern Laboratory Medicine,2023,38(06):191.[doi:10.3969/j.issn.1671-7414.2023.01.036]
[6]唐红辉,李洪春.基于吖啶酯化学发光免疫定量分析技术建立血清IL-6 水平检测方法与初步应用评价[J].现代检验医学杂志,2024,39(04):175.[doi:10.3969/j.issn.1671-7414.2024.04.032]
　TANG Honghui,LI Hongchun.Establishment of the Detection Method of Serum IL-6 Level and Its Preliminary Application Evaluation based on Acridine Ester Chemiluminescence Immune Quantitative Analysis Technology[J].Journal of Modern Laboratory Medicine,2024,39(06):175.[doi:10.3969/j.issn.1671-7414.2024.04.032]

备注/Memo

备注/Memo:
基金项目： 云南省科技厅科技计划项目（202201AY070001-058）：DNMT1 在记忆性NK 细胞对急性髓系白血病细胞抑制作用的机制研究；云南省“高层次人才培养支持计划”名医专项基金资助项目（RLMY20200020）。
作者简介：武坤（1981-），男，医学博士，主管检验师，研究方向：恶性血液病临床检测，E-mail：wukunnana@126.com。
更新日期/Last Update: 2023-11-15